Modulo Bio, a medical research company focused on the neuroimmune system, has announced that it has been awarded a $4.8 million grant from the Alzheimer’s Drug Discovery Foundation (ADDF). The funding will be used to advance the development of its lead therapeutic candidate, MOD 001, a CSF1R (colony stimulating factor 1 receptor) inhibitor, for the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis.
MOD 001 represents a new approach to treating neurodegenerative diseases through modulation of the neuroimmune system. The company’s small-molecule therapeutic specifically targets CSF1R and demonstrates exceptional blood-brain barrier penetration, a critical feature for treating neurological conditions
“The ADDF’s endorsement strongly validates our focus on combating neuroinflammation in degenerative brain disorders,” said Modulo Bio CEO Michael Horowitz. “Their scientific team has conducted thorough due diligence on MOD 001 as a potential treatment for FTD, a devastating early-onset form of dementia that currently lacks any disease-modifying therapies.”
With this funding, Modulo Bio aims to further advance the development of MOD 001, bringing hope to patients and families affected by FTD and other neurodegenerative diseases
Please don’t forget to “Allow the notification” so you will be the first to get our gist when we publish it.
Drop your comment in the section below, and don’t forget to share the post.
Keep up with the latest news and be part of our weekly giveaways and airtime…
Keep up with the latest news and be part of our weekly giveaways and airtime…
Keep up with the latest news and be part of our weekly giveaways and airtime…
Keep up with the latest news and be part of our weekly giveaways and airtime…
Keep up with the latest news and be part of our weekly giveaways and airtime…
Keep up with the latest news and be part of our weekly giveaways and airtime…